BiotechTube

Nimotuzumab + Temozolomide

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Glioblastoma

Conditions

Glioblastoma

Trial Timeline

Aug 18, 2010 → Mar 23, 2017

NCT ID
NCT03388372

About Nimotuzumab + Temozolomide

Nimotuzumab + Temozolomide is a phase 2 stage product being developed by Sun Pharmaceutical for Glioblastoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03388372. Target conditions include Glioblastoma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT03388372Phase 2Completed

Competing Products

20 competing products in Glioblastoma

See all competitors
ProductCompanyStageHype Score
TemferonGenenta SciencePhase 1/2
33
PLX3397 + TemozolomideDaiichi SankyoPhase 1/2
41
PLX3397Daiichi SankyoPhase 2
52
ASP8374 + cemiplimabAstellas PharmaPhase 1
33
Gliadel + Avastin + TemodarEisaiPhase 2
52
BCNU Wafer + Irinotecan + BevacizumabEisaiPhase 1/2
41
KHK2455Kyowa KirinPre-clinical
23
olaratumab + ramucirumabEli LillyPhase 2
52
enzastaurin + temozolomideEli LillyPhase 1/2
41
enzastaurin + bevacizumab + Enzyme-inducing antiepileptic drugs (EIAED) + Non-enzyme inducing antiepileptic drugs (NEIAED)Eli LillyPhase 2
52
Temozolomide + Neratinib + QBS10072S + Abemaciclib + CC-115Eli LillyPhase 2
52
AbemaciclibEli LillyPhase 2
52
Enzastaurin 500 milligram (mg) Once Daily (QD) + Enzastaurin 250 mg Twice Daily (BID)Eli LillyPhase 2
52
Abemaciclib + LY3214996Eli LillyPhase 1
33
enzastaurin + lomustineEli LillyPhase 3
77
Galunisertib + Lomustine + PlaceboEli LillyPhase 2
52
DSP-7888 Dosing Emulsion + BevacizumabSumitomo PharmaPhase 3
77
DSP-7888Sumitomo PharmaPhase 1/2
41
BBI608 + TemozolomideSumitomo PharmaPhase 1/2
41
Indoximod + Temozolomide + Cyclophosphamide + Etoposide + LomustineJohnson & JohnsonPhase 2
52

Other Products from Sun Pharmaceutical

Ilumya Injectable ProductApproved
85
CequaTM (Cyclosporine 0.09%) ophthalmic solutionApproved
85
Cyclosporine + Artificial tearApproved
85
AmifostineApproved
85
Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy + Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapyApproved
85